research Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.
Search
for
Sort by
Research
12 / 12 results research Discovering Hair Loss Treatments That Increase The Wnt/Beta-Catenin Signaling Pathway By High-Throughput Screening
Aminoacridine and Abemaciclib, especially combined with Minoxidil, show promise for treating hair loss.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
research Cutaneous Toxicities of New Targeted Cancer Therapies: Must Know for Diagnosis, Management, and Patient-Proxy Empowerment
New targeted cancer drugs can cause skin side effects, and managing them requires patient education and timely care.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Managing Hyperglycemia and Rash Associated With Alpelisib: Expert Consensus Recommendations Using the Delphi Technique
Experts agree on how to manage sugar levels and skin reactions in patients taking the cancer drug alpelisib.
research Kalya Research: Complementary and Alternative Medicine Virtual Research Assistant from Biomedical Literature
Kalya Research is an AI tool that effectively finds and analyzes alternative medicine literature, saving researchers time.
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Estrogen Deprivation Effects of Endocrine Therapy in Breast Cancer Patients: Incidence, Management and Outcome
Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force Dermatology for Cancer Patients International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment, and Prevention
Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.